|
Volumn 14, Issue 12, 2013, Pages 1433-1443
|
Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIINFLAMMATORY AGENT;
BIOLOGICAL PRODUCT;
IMMUNOGLOBULIN;
INTEGRIN;
INTEGRIN ALPHA4BETA7;
MADCAM1 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
MUCOPROTEIN;
VEDOLIZUMAB;
DRUG ANTAGONISM;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
INFLAMMATORY BOWEL DISEASE;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BIOLOGICAL PRODUCTS;
HUMANS;
IMMUNOGLOBULINS;
INFLAMMATORY BOWEL DISEASES;
INTEGRINS;
MOLECULAR TARGETED THERAPY;
MUCOPROTEINS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
MLCS;
MLOWN;
|
EID: 84897070797
PISSN: None
EISSN: 18735592
Source Type: Journal
DOI: 10.2174/13894501113146660206 Document Type: Review |
Times cited : (55)
|
References (0)
|